Cellgene Tx News

The latest cellgene tx stories, summarized by AI

BMS claims Phase 2 success for GPRC5D-directed CAR-T in myeloma

Bristol Myers Squibb claims Phase 2 success for a GPRC5D-targeted CAR-T therapy in multiple myeloma, underscoring the potential of this target while noting ongoing questions about durability and outcomes after progression.

1 hour ago•Source: Endpoints News

Featured Cellgene Tx Stories

BMS claims Phase 2 success for GPRC5D-directed CAR-T in myeloma

More Cellgene Tx Stories